

We never stop at Amyl Therapeutics !🚀
On April 29th, our CEO, Pierre Vandepapelière, attended the LSX World Congress conference that took place at the Business Design Center in London.
During this leading event dedicated to innovation and investment in the life sciences and healthcare sector, he had the opportunity to present our Pan-Amyloid Immunotherapy technology, a groundbreaking approach designed to become a universal treatment for neurodegenerative diseases.